Qiagen (QGEN) Tops Q1 EPS by 7c; Suspends Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
QIAGEN Reports Full Results for First Quarter of 2020
May 6, 2020 4:05 PM EDTQ1 2020 results: Net sales of $372.1 million (+7% actual, +9% CER vs. ~+2-3% CER outlook) Diluted EPS $0.17; adjusted EPS $0.34 ($0.34 CER vs. ~$0.28-0.29 CER outlook) Fully mobilized teams addressing COVID-19 pandemic testing demand, dramatically ramping up production of RNA extraction kits, QIAstat-Dx tests and components for third-party tests QIAGEN expects higher results for Q2 2020 based on trends to date and suspends outlook for full-year 2020
VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:... More



